Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
more,27733484,recoveries,The recoveries at three levels were more than 66.2%.,"Determination of the Metabolite of Ephedrine, 4-Hydroxyephedrine, by LC-MS-MS in Rat Urine and Its Application in Excretion Profiles After Oral Administration of Ephedra sinica Stapf and Processing Ephedra sinica Stapf. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27733484/),%,66.2,13361,DB01364,Ephedrine
,9712471,Vss/F,"Gender-based comparisons of Vss/F and CL/F revealed higher values for women than for men (Vss/F, 3.49 +/- 1.04 vs 2.98 +/- 0.73 l/kg; CL/F, 0.48 +/- 0.11 vs 0.37 +/- 0.11 l/hour x kg).",Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712471/),[l] / [kg],3.49,13965,DB01364,Ephedrine
,9712471,Vss/F,"Gender-based comparisons of Vss/F and CL/F revealed higher values for women than for men (Vss/F, 3.49 +/- 1.04 vs 2.98 +/- 0.73 l/kg; CL/F, 0.48 +/- 0.11 vs 0.37 +/- 0.11 l/hour x kg).",Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712471/),[l] / [kg],2.98,13966,DB01364,Ephedrine
,9712471,CL/F,"Gender-based comparisons of Vss/F and CL/F revealed higher values for women than for men (Vss/F, 3.49 +/- 1.04 vs 2.98 +/- 0.73 l/kg; CL/F, 0.48 +/- 0.11 vs 0.37 +/- 0.11 l/hour x kg).",Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712471/),[l] / [h·kg],0.48,13967,DB01364,Ephedrine
,9712471,CL/F,"Gender-based comparisons of Vss/F and CL/F revealed higher values for women than for men (Vss/F, 3.49 +/- 1.04 vs 2.98 +/- 0.73 l/kg; CL/F, 0.48 +/- 0.11 vs 0.37 +/- 0.11 l/hour x kg).",Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712471/),[l] / [h·kg],0.37,13968,DB01364,Ephedrine
,15303659,recovery,"The within-day and between-day RSD were less than 12.4%, and the average recovery was between 97.3% - 109.4%.",[Simultaneous determination of pseudoephedrine and chlorpheniramine in human plasma by HPLC-UV detection method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15303659/),%,97.3,14290,DB01364,Ephedrine
,15303659,recovery,"The within-day and between-day RSD were less than 12.4%, and the average recovery was between 97.3% - 109.4%.",[Simultaneous determination of pseudoephedrine and chlorpheniramine in human plasma by HPLC-UV detection method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15303659/),%,109.4,14291,DB01364,Ephedrine
,15060505,peak difference,"Ephedrine plus caffeine increased systolic blood pressure (peak difference, 11.7 +/- 9.4 mm Hg; compared with placebo, P =.0005) and heart rate (peak difference, 5.9 +/- 8.8 beats/min; compared with placebo, P =.001) and raised fasting glucose, insulin, free fatty acid, and lactate concentrations.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),hg·mm,11.7,14939,DB01364,Ephedrine
,15060505,peak difference,"Ephedrine plus caffeine increased systolic blood pressure (peak difference, 11.7 +/- 9.4 mm Hg; compared with placebo, P =.0005) and heart rate (peak difference, 5.9 +/- 8.8 beats/min; compared with placebo, P =.001) and raised fasting glucose, insulin, free fatty acid, and lactate concentrations.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),[beats] / [min],5.9,14940,DB01364,Ephedrine
,15060505,elimination half-life,"Women taking oral contraceptives had prolonged caffeine elimination (mean elimination half-life, 9.7 hours versus 5.0 hours in men; P =.05), but sex differences in pharmacodynamic responses were not seen.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),h,9.7,14941,DB01364,Ephedrine
,15060505,elimination half-life,"Women taking oral contraceptives had prolonged caffeine elimination (mean elimination half-life, 9.7 hours versus 5.0 hours in men; P =.05), but sex differences in pharmacodynamic responses were not seen.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),h,5.0,14942,DB01364,Ephedrine
,11438965,T(max),"The T(max), AUC, C(max) and t(1/2) were 30 min, 7.8 x 10(2) (ng/mL) min, 39 ng/mL and 1.7 x 10(2) min.",Determination of trimebutine maleate in rat plasma and tissues by using capillary zone electrophoresis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11438965/),min,30,18233,DB01364,Ephedrine
,11438965,AUC,"The T(max), AUC, C(max) and t(1/2) were 30 min, 7.8 x 10(2) (ng/mL) min, 39 ng/mL and 1.7 x 10(2) min.",Determination of trimebutine maleate in rat plasma and tissues by using capillary zone electrophoresis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11438965/),[ng] / [ml],39,18234,DB01364,Ephedrine
,11438965,C(max),"The T(max), AUC, C(max) and t(1/2) were 30 min, 7.8 x 10(2) (ng/mL) min, 39 ng/mL and 1.7 x 10(2) min.",Determination of trimebutine maleate in rat plasma and tissues by using capillary zone electrophoresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11438965/),[ng] / [ml],39,18235,DB01364,Ephedrine
,11438965,t(1/2),"The T(max), AUC, C(max) and t(1/2) were 30 min, 7.8 x 10(2) (ng/mL) min, 39 ng/mL and 1.7 x 10(2) min.",Determination of trimebutine maleate in rat plasma and tissues by using capillary zone electrophoresis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11438965/),min,1.7 x 10(2),18236,DB01364,Ephedrine
,26724253,m/z,"Multiple reaction monitoring (MRM) was used to monitor m/z 166.1→148.1 for ephedrine ([M+H](+)), 475.2→163.0 for amygdalin ([M+NH4](+)), and 840.6→453.3 ([M+NH4](+)) for glycyrrhizic acid.","Determination the active compounds of herbal preparation by UHPLC-MS/MS and its application on the preclinical pharmacokinetics of pure ephedrine, single herbal extract of Ephedra, and a multiple herbal preparation in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724253/),,166.1,21527,DB01364,Ephedrine
,26724253,m/z,"Multiple reaction monitoring (MRM) was used to monitor m/z 166.1→148.1 for ephedrine ([M+H](+)), 475.2→163.0 for amygdalin ([M+NH4](+)), and 840.6→453.3 ([M+NH4](+)) for glycyrrhizic acid.","Determination the active compounds of herbal preparation by UHPLC-MS/MS and its application on the preclinical pharmacokinetics of pure ephedrine, single herbal extract of Ephedra, and a multiple herbal preparation in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724253/),,148.1,21528,DB01364,Ephedrine
,26724253,m/z,"Multiple reaction monitoring (MRM) was used to monitor m/z 166.1→148.1 for ephedrine ([M+H](+)), 475.2→163.0 for amygdalin ([M+NH4](+)), and 840.6→453.3 ([M+NH4](+)) for glycyrrhizic acid.","Determination the active compounds of herbal preparation by UHPLC-MS/MS and its application on the preclinical pharmacokinetics of pure ephedrine, single herbal extract of Ephedra, and a multiple herbal preparation in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724253/),,475.2,21529,DB01364,Ephedrine
,26724253,m/z,"Multiple reaction monitoring (MRM) was used to monitor m/z 166.1→148.1 for ephedrine ([M+H](+)), 475.2→163.0 for amygdalin ([M+NH4](+)), and 840.6→453.3 ([M+NH4](+)) for glycyrrhizic acid.","Determination the active compounds of herbal preparation by UHPLC-MS/MS and its application on the preclinical pharmacokinetics of pure ephedrine, single herbal extract of Ephedra, and a multiple herbal preparation in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724253/),,163.0,21530,DB01364,Ephedrine
,26724253,m/z,"Multiple reaction monitoring (MRM) was used to monitor m/z 166.1→148.1 for ephedrine ([M+H](+)), 475.2→163.0 for amygdalin ([M+NH4](+)), and 840.6→453.3 ([M+NH4](+)) for glycyrrhizic acid.","Determination the active compounds of herbal preparation by UHPLC-MS/MS and its application on the preclinical pharmacokinetics of pure ephedrine, single herbal extract of Ephedra, and a multiple herbal preparation in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724253/),,840.6,21531,DB01364,Ephedrine
,26724253,m/z,"Multiple reaction monitoring (MRM) was used to monitor m/z 166.1→148.1 for ephedrine ([M+H](+)), 475.2→163.0 for amygdalin ([M+NH4](+)), and 840.6→453.3 ([M+NH4](+)) for glycyrrhizic acid.","Determination the active compounds of herbal preparation by UHPLC-MS/MS and its application on the preclinical pharmacokinetics of pure ephedrine, single herbal extract of Ephedra, and a multiple herbal preparation in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724253/),,453.3,21532,DB01364,Ephedrine
,26724253,elimination half-life,"However, the elimination half-life of ephedrine administered as the pure compound was 93.9±8.07min, but for ephedrine from the Ephedra extract and the MXGST, the half-lives were 133±17 and 247±57.6min, respectively.","Determination the active compounds of herbal preparation by UHPLC-MS/MS and its application on the preclinical pharmacokinetics of pure ephedrine, single herbal extract of Ephedra, and a multiple herbal preparation in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724253/),min,93.9,21533,DB01364,Ephedrine
,26724253,half-lives,"However, the elimination half-life of ephedrine administered as the pure compound was 93.9±8.07min, but for ephedrine from the Ephedra extract and the MXGST, the half-lives were 133±17 and 247±57.6min, respectively.","Determination the active compounds of herbal preparation by UHPLC-MS/MS and its application on the preclinical pharmacokinetics of pure ephedrine, single herbal extract of Ephedra, and a multiple herbal preparation in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724253/),min,133,21534,DB01364,Ephedrine
,26724253,half-lives,"However, the elimination half-life of ephedrine administered as the pure compound was 93.9±8.07min, but for ephedrine from the Ephedra extract and the MXGST, the half-lives were 133±17 and 247±57.6min, respectively.","Determination the active compounds of herbal preparation by UHPLC-MS/MS and its application on the preclinical pharmacokinetics of pure ephedrine, single herbal extract of Ephedra, and a multiple herbal preparation in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724253/),min,247,21535,DB01364,Ephedrine
,33171336,total flow,"UFLC separation was performed on a Thermo Scientific AcclaimTM RSLC 120 C18 column (2.1 mm × 100 mm, 2.2 μm) with mobile phase containing methanol and 0.1% formic acid-water by gradient elution in 8.1 min at total flow of 0.3 mL/min.",Simultaneous determination of nine constituents by validated UFLC-MS/MS in the plasma of cough variant asthma rats and its application to pharmacokinetic study after oral administration of Huanglong cough oral liquid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33171336/),[ml] / [min],0.3,29282,DB01364,Ephedrine
,12579881,recovery,The recovery for trimebutine maleate in rat plasma was 72.8%-87.9%.,[HPCE determination of trimebutine maleate in rat plasma and its pharmacokinetics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579881/),%,72.8,37280,DB01364,Ephedrine
,12579881,recovery,The recovery for trimebutine maleate in rat plasma was 72.8%-87.9%.,[HPCE determination of trimebutine maleate in rat plasma and its pharmacokinetics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579881/),%,87.9,37281,DB01364,Ephedrine
,12579881,AUC0-infinity,"The pharmacokinetic results were AUC0-infinity = 8 micrograms.min.mL-1, T1/2(Ke) = 173 min and Ke = 5.6 x 10(-3) min-1.",[HPCE determination of trimebutine maleate in rat plasma and its pharmacokinetics]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579881/),[min·μg] / [ml],8,37282,DB01364,Ephedrine
,12579881,T1/2(Ke),"The pharmacokinetic results were AUC0-infinity = 8 micrograms.min.mL-1, T1/2(Ke) = 173 min and Ke = 5.6 x 10(-3) min-1.",[HPCE determination of trimebutine maleate in rat plasma and its pharmacokinetics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579881/),min,173,37283,DB01364,Ephedrine
,12579881,Ke,"The pharmacokinetic results were AUC0-infinity = 8 micrograms.min.mL-1, T1/2(Ke) = 173 min and Ke = 5.6 x 10(-3) min-1.",[HPCE determination of trimebutine maleate in rat plasma and its pharmacokinetics]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579881/),1/[min],5.6 x 10(-3),37284,DB01364,Ephedrine
,3403107,maximum plasma concentrations (Cmax),"Medians of maximum plasma concentrations (Cmax) of oxilofrine were 9.1 ng/ml, 11.4 ng/ml, 31.4 ng/ml and 122.9 ng/ml for 16 mg drops, 16, 32, and 64 mg dragées, respectively.","Dose linearity and relative bioavailability testing of oxilofrine, a sympathicomimetic drug, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403107/),[ng] / [ml],9.1,39746,DB01364,Ephedrine
,3403107,maximum plasma concentrations (Cmax),"Medians of maximum plasma concentrations (Cmax) of oxilofrine were 9.1 ng/ml, 11.4 ng/ml, 31.4 ng/ml and 122.9 ng/ml for 16 mg drops, 16, 32, and 64 mg dragées, respectively.","Dose linearity and relative bioavailability testing of oxilofrine, a sympathicomimetic drug, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403107/),[ng] / [ml],11.4,39747,DB01364,Ephedrine
,3403107,maximum plasma concentrations (Cmax),"Medians of maximum plasma concentrations (Cmax) of oxilofrine were 9.1 ng/ml, 11.4 ng/ml, 31.4 ng/ml and 122.9 ng/ml for 16 mg drops, 16, 32, and 64 mg dragées, respectively.","Dose linearity and relative bioavailability testing of oxilofrine, a sympathicomimetic drug, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403107/),[ng] / [ml],31.4,39748,DB01364,Ephedrine
,3403107,maximum plasma concentrations (Cmax),"Medians of maximum plasma concentrations (Cmax) of oxilofrine were 9.1 ng/ml, 11.4 ng/ml, 31.4 ng/ml and 122.9 ng/ml for 16 mg drops, 16, 32, and 64 mg dragées, respectively.","Dose linearity and relative bioavailability testing of oxilofrine, a sympathicomimetic drug, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403107/),[ng] / [ml],122.9,39749,DB01364,Ephedrine
,3403107,times to maximum plasma concentration (tmax),"The times to maximum plasma concentration (tmax) were between 0.7 and 1.7 h, respectively.","Dose linearity and relative bioavailability testing of oxilofrine, a sympathicomimetic drug, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403107/),h,0.7,39750,DB01364,Ephedrine
,3403107,times to maximum plasma concentration (tmax),"The times to maximum plasma concentration (tmax) were between 0.7 and 1.7 h, respectively.","Dose linearity and relative bioavailability testing of oxilofrine, a sympathicomimetic drug, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403107/),h,1.7,39751,DB01364,Ephedrine
,3403107,areas under the plasma concentration-time curve (AUC0-24),"The values for areas under the plasma concentration-time curve (AUC0-24) were 12.8, 17.7, 61.0 and 268.2 ng/ml.h for the four treatments.","Dose linearity and relative bioavailability testing of oxilofrine, a sympathicomimetic drug, in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403107/),[ng] / [h·ml],12.8,39752,DB01364,Ephedrine
,3403107,areas under the plasma concentration-time curve (AUC0-24),"The values for areas under the plasma concentration-time curve (AUC0-24) were 12.8, 17.7, 61.0 and 268.2 ng/ml.h for the four treatments.","Dose linearity and relative bioavailability testing of oxilofrine, a sympathicomimetic drug, in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403107/),[ng] / [h·ml],17.7,39753,DB01364,Ephedrine
,3403107,areas under the plasma concentration-time curve (AUC0-24),"The values for areas under the plasma concentration-time curve (AUC0-24) were 12.8, 17.7, 61.0 and 268.2 ng/ml.h for the four treatments.","Dose linearity and relative bioavailability testing of oxilofrine, a sympathicomimetic drug, in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403107/),[ng] / [h·ml],61.0,39754,DB01364,Ephedrine
,3403107,areas under the plasma concentration-time curve (AUC0-24),"The values for areas under the plasma concentration-time curve (AUC0-24) were 12.8, 17.7, 61.0 and 268.2 ng/ml.h for the four treatments.","Dose linearity and relative bioavailability testing of oxilofrine, a sympathicomimetic drug, in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403107/),[ng] / [h·ml],268.2,39755,DB01364,Ephedrine
,8917241,terminal elimination half-life,"In children, the mean (+/-SEM) terminal elimination half-life values for pseudoephedrine, 3.1 +/- 0.5 hours, and for phenylpropanolamine, 2.6 +/- 0.6 hours, were significantly shorter than those found by other investigators in adults.",Pharmacokinetics of the orally administered decongestants pseudoephedrine and phenylpropanolamine in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917241/),h,3.1,52266,DB01364,Ephedrine
,8917241,terminal elimination half-life,"In children, the mean (+/-SEM) terminal elimination half-life values for pseudoephedrine, 3.1 +/- 0.5 hours, and for phenylpropanolamine, 2.6 +/- 0.6 hours, were significantly shorter than those found by other investigators in adults.",Pharmacokinetics of the orally administered decongestants pseudoephedrine and phenylpropanolamine in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917241/),h,2.6,52267,DB01364,Ephedrine
,870547,half-life (t1/2),"After treatment with ephedrine, there was a mean decrease in plasma dexamethasone half-life (t1/2) of 132 minutes, or 36 per cent (P less than 0.025), and mean increase in metabolic clearance rate (MCR) of 148 liters/day, or 42 per cent (P less than 0.001).",The effects of ephedrine and theophylline on dexamethasone metabolism in bronchial asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/870547/),min,132,58326,DB01364,Ephedrine
,7507589,bioavailability,"Both PPA and PDE are readily and completely absorbed, whereas PE, with a bioavailability of only approximately 38%, is subject to gut wall metabolism and is thought to be absorbed erratically.",Pharmacokinetics of oral decongestants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),%,38,59010,DB01364,Ephedrine
,7507589,apparent volume of distribution,All three drugs are extensively distributed into extravascular sites (apparent volume of distribution between 2.6 and 5.0 L/kg).,Pharmacokinetics of oral decongestants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),[l] / [kg],2.6 and 5.0,59011,DB01364,Ephedrine
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,2.5,59012,DB01364,Ephedrine
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,4,59013,DB01364,Ephedrine
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,6,59014,DB01364,Ephedrine
,19021932,peak concentration,"However, the highest amount of ephedrines in urine was ephedrine and the peak concentration was 4.35 +/- 1.82 microg/mL (mean +/- standard deviation), which was lower than the WADA permitted value (10 microg/mL).",Urinary elimination of ephedrines following administration of the Traditional Chinese Medicine preparation Kakkon-to. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021932/),[μg] / [ml],4.35,61476,DB01364,Ephedrine
,19021932,peak concentration,"However, the highest amount of ephedrines in urine was ephedrine and the peak concentration was 4.35 +/- 1.82 microg/mL (mean +/- standard deviation), which was lower than the WADA permitted value (10 microg/mL).",Urinary elimination of ephedrines following administration of the Traditional Chinese Medicine preparation Kakkon-to. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021932/),,10,61477,DB01364,Ephedrine
,19021932,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were: 5.2 +/- 1.2, 4.2 +/- 1.3, 4.2 +/- 0.9, and 6.5 +/- 2.8 h, respectively.",Urinary elimination of ephedrines following administration of the Traditional Chinese Medicine preparation Kakkon-to. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021932/),h,5.2,61478,DB01364,Ephedrine
,19021932,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were: 5.2 +/- 1.2, 4.2 +/- 1.3, 4.2 +/- 0.9, and 6.5 +/- 2.8 h, respectively.",Urinary elimination of ephedrines following administration of the Traditional Chinese Medicine preparation Kakkon-to. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021932/),h,4.2,61479,DB01364,Ephedrine
,19021932,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were: 5.2 +/- 1.2, 4.2 +/- 1.3, 4.2 +/- 0.9, and 6.5 +/- 2.8 h, respectively.",Urinary elimination of ephedrines following administration of the Traditional Chinese Medicine preparation Kakkon-to. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021932/),h,4.2,61480,DB01364,Ephedrine
,19021932,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were: 5.2 +/- 1.2, 4.2 +/- 1.3, 4.2 +/- 0.9, and 6.5 +/- 2.8 h, respectively.",Urinary elimination of ephedrines following administration of the Traditional Chinese Medicine preparation Kakkon-to. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021932/),h,6.5,61481,DB01364,Ephedrine
,33298381,recoveries,The recoveries of MET and EPD from the mice plasma and brain ranged from 108.5 to 112.1%.,Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),%,108.5 to 112.1,62129,DB01364,Ephedrine
,33298381,Cmax,The results exhibited that the Cmax and Tmax of MET in mice plasma was 517.1 ng/mL and 15 min as compared to 3.6 ng/mL and 2 h of EPD.,Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),[ng] / [ml],517.1,62130,DB01364,Ephedrine
,33298381,Cmax,The results exhibited that the Cmax and Tmax of MET in mice plasma was 517.1 ng/mL and 15 min as compared to 3.6 ng/mL and 2 h of EPD.,Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),[ng] / [ml],3.6,62131,DB01364,Ephedrine
,33298381,Tmax,The results exhibited that the Cmax and Tmax of MET in mice plasma was 517.1 ng/mL and 15 min as compared to 3.6 ng/mL and 2 h of EPD.,Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),min,15,62132,DB01364,Ephedrine
,33298381,Tmax,The results exhibited that the Cmax and Tmax of MET in mice plasma was 517.1 ng/mL and 15 min as compared to 3.6 ng/mL and 2 h of EPD.,Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),h,2,62133,DB01364,Ephedrine
,33298381,Cmax,"Moreover, MET rapidly passed the blood brain barrier with Cmax of 1444.5 ng/mL achieved at 15 min, whereas, EPD monitored Cmax of 43.6 ng/mL at 4 h in mice brain.",Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),[ng] / [ml],1444.5,62134,DB01364,Ephedrine
,33298381,Cmax,"Moreover, MET rapidly passed the blood brain barrier with Cmax of 1444.5 ng/mL achieved at 15 min, whereas, EPD monitored Cmax of 43.6 ng/mL at 4 h in mice brain.",Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),[ng] / [ml],43.6,62135,DB01364,Ephedrine
,15089807,EC50,The mean maximum predicted effect (Emax) was 53.7% (CV = 41%) with an EC50 of 107 microg.l(-1) (CV = 65%) and an inhibitory maximum (Imax) of 39.8% (CV = 60%).,Modelling the cardiovascular effects of ephedrine. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089807/),[μg] / [l],107,62700,DB01364,Ephedrine
,15089807,half-life,Tolerance developed with a mean half-life of 15 min (range 6-140 min).,Modelling the cardiovascular effects of ephedrine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089807/),min,15,62701,DB01364,Ephedrine
,16671554,flow rate,"The analytes and the internal standard, diphenhydramine, were isolated from plasma by protein precipitation with methanol, then chromatographied on a Zorbax SB-C18 column (150 mm x 4.6 mm ID) using a mobile phase consisted of methanol-water-formic acid (80: 20: 0.5, v/v), at a flow rate of 0.5 mL x min(-1).",[Simultaneous determination of ephedrine and chlorpheniramine in human plasma by a highly sensitive liquid chromatography-tandem mass spectrometric method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671554/),[ml] / [min],0.5,67438,DB01364,Ephedrine
,1820895,Peak plasma PPA levels,Peak plasma PPA levels were slightly higher for the transdermal patch compared with the tablet formulation (93.6 ng/ml versus 80.10 ng/ml respectively).,In-vivo pharmacokinetic characteristics of a transdermal phenylpropanolamine (PPA) preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820895/),[ng] / [ml],93.6,69362,DB01364,Ephedrine
,1820895,Peak plasma PPA levels,Peak plasma PPA levels were slightly higher for the transdermal patch compared with the tablet formulation (93.6 ng/ml versus 80.10 ng/ml respectively).,In-vivo pharmacokinetic characteristics of a transdermal phenylpropanolamine (PPA) preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820895/),[ng] / [ml],80.10,69363,DB01364,Ephedrine
,30081350,flow rate,"These four components were separated using water containing 0.01% formic acid and methanol as a mobile phase by gradient elution at a flow rate of 0.3 mL/min with a HALO-C18 column (2.1 mm × 100 mm, 2.7 μm particle size).",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),[ml] / [min],0.3,87010,DB01364,Ephedrine
,30081350,Mass transitions,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,432.9,87011,DB01364,Ephedrine
,30081350,Mass transitions,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,384.1,87012,DB01364,Ephedrine
,30081350,Mass transitions,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,165.8,87013,DB01364,Ephedrine
,30081350,Mass transitions,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,525.0,87014,DB01364,Ephedrine
,30081350,Mass transitions,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,146.8,87015,DB01364,Ephedrine
,30081350,Mass transitions,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,340.0,87016,DB01364,Ephedrine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,432.9,87017,DB01364,Ephedrine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,384.1,87018,DB01364,Ephedrine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,165.8,87019,DB01364,Ephedrine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,148.1,87020,DB01364,Ephedrine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,525.0,87021,DB01364,Ephedrine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,449.2,87022,DB01364,Ephedrine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,146.8,87023,DB01364,Ephedrine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,102.9,87024,DB01364,Ephedrine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,340.0,87025,DB01364,Ephedrine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,324.0,87026,DB01364,Ephedrine
,7690382,maximum concentration,"The mean maximum concentration in plasma for midodrine was 10 ng/ml 20-30 min after oral administration, for ST 1059 5 ng/ml after 1 h.",Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690382/),[ng] / [ml],10,94148,DB01364,Ephedrine
,7690382,maximum concentration,"The mean maximum concentration in plasma for midodrine was 10 ng/ml 20-30 min after oral administration, for ST 1059 5 ng/ml after 1 h.",Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690382/),[ng] / [ml],5,94149,DB01364,Ephedrine
,7690382,terminal half-life,"Midodrine was eliminated with a terminal half-life of 0.5 h, ST 1059 with a half-life of 3 hrs.",Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690382/),h,0.5,94150,DB01364,Ephedrine
,7690382,half-life,"Midodrine was eliminated with a terminal half-life of 0.5 h, ST 1059 with a half-life of 3 hrs.",Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690382/),h,3,94151,DB01364,Ephedrine
,7690382,area under the plasma-level vs. time curve (AUC),"The mean area under the plasma-level vs. time curve (AUC) of ST 1059 after administration of 2.5 mg midodrine i.v. was 28.7 ng x h/ml, and similar for the other formulations which are considered to be bioequivalent.",Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690382/),[h·ng] / [ml],28.7,94152,DB01364,Ephedrine
,16971194,ch,"The method had a chromatographic run time of 12.0 min and a linear calibration curve over the concentration range of 1.0-800 ng/ml for pseudoephedrine and 1.0-400 ng/ml for cetirizine, respectively.",Development and evaluation of an efficient HPLC/MS/MS method for the simultaneous determination of pseudoephedrine and cetirizine in human plasma: application to phase-I pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971194/),min,12.0,99830,DB01364,Ephedrine
,16971194,run time,"The method had a chromatographic run time of 12.0 min and a linear calibration curve over the concentration range of 1.0-800 ng/ml for pseudoephedrine and 1.0-400 ng/ml for cetirizine, respectively.",Development and evaluation of an efficient HPLC/MS/MS method for the simultaneous determination of pseudoephedrine and cetirizine in human plasma: application to phase-I pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971194/),min,12.0,99831,DB01364,Ephedrine
,19371465,peak concentration,"The peak concentration of ephedrine was 3.88 +/- 1.87 mg/mL (mean +/- SD), which was lower than the WADA permitted value (10 mg/mL).",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),[mg] / [ml],3.88,110077,DB01364,Ephedrine
,19371465,peak concentration,"The peak concentration of ephedrine was 3.88 +/- 1.87 mg/mL (mean +/- SD), which was lower than the WADA permitted value (10 mg/mL).",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),,10,110078,DB01364,Ephedrine
,19371465,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were 5.3 +/- 1.2, 4.9 +/- 0.9, 4.4 +/- 1.0, and 5.4 +/- 1.8 h, respectively.",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),h,5.3,110079,DB01364,Ephedrine
,19371465,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were 5.3 +/- 1.2, 4.9 +/- 0.9, 4.4 +/- 1.0, and 5.4 +/- 1.8 h, respectively.",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),h,4.9,110080,DB01364,Ephedrine
,19371465,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were 5.3 +/- 1.2, 4.9 +/- 0.9, 4.4 +/- 1.0, and 5.4 +/- 1.8 h, respectively.",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),h,4.4,110081,DB01364,Ephedrine
,19371465,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were 5.3 +/- 1.2, 4.9 +/- 0.9, 4.4 +/- 1.0, and 5.4 +/- 1.8 h, respectively.",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),h,5.4,110082,DB01364,Ephedrine
,15953705,flow rate,Chromatographic separation was performed on an ODS column at flow rate of 0.2 ml/min.,Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[ml] / [min],0.2,111725,DB01364,Ephedrine
,15953705,total chromatographic run time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,10.5,111726,DB01364,Ephedrine
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,7.1,111727,DB01364,Ephedrine
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,6.2,111728,DB01364,Ephedrine
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,2.2,111729,DB01364,Ephedrine
,15953705,LOQ,"The LOQ was 10 pg/ml and 50 pg/ml for LOR and PES, respectively.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[pg] / [ml],10,111730,DB01364,Ephedrine
,15953705,LOQ,"The LOQ was 10 pg/ml and 50 pg/ml for LOR and PES, respectively.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[pg] / [ml],50,111731,DB01364,Ephedrine
,14671681,relative bioavailability,"Furthermore, a relative bioavailability of approximately 100% of the preliminary formulation was shown for the newly developed formulation for all parameters.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),%,100,122142,DB01364,Ephedrine
,14671681,AUC,"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [h·l],1040.66,122143,DB01364,Ephedrine
,14671681,AUC,"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [h·l],142.28,122144,DB01364,Ephedrine
,14671681,C(max),"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [l],134.52,122145,DB01364,Ephedrine
,14671681,C(max),"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [l],30.34,122146,DB01364,Ephedrine
,14671681,t(max),The median t(max) values were 0.67 h for PSE and 0.92 h for SA.,Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),h,0.67,122147,DB01364,Ephedrine
,14671681,t(max),The median t(max) values were 0.67 h for PSE and 0.92 h for SA.,Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),h,0.92,122148,DB01364,Ephedrine
,16969767,linear dynamic ranges,"The method exhibited linear dynamic ranges of 1-500 ng/mL and 2-1000 ng/mL for fexofenadine and pseudoephedrine, respectively, in human plasma.","Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969767/),[ng] / [ml],1-500,123213,DB01364,Ephedrine
,16969767,linear dynamic ranges,"The method exhibited linear dynamic ranges of 1-500 ng/mL and 2-1000 ng/mL for fexofenadine and pseudoephedrine, respectively, in human plasma.","Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969767/),[ng] / [ml],2-1000,123214,DB01364,Ephedrine
,16969767,total chromatographic run time,The total chromatographic run time was 2 min and more than 400 human plasma samples could be analyzed in one day by running the system overnight.,"Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969767/),min,2,123215,DB01364,Ephedrine
,11824817,run time,The run time was 4 min.,Rapid determination of pseudoephedrine in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11824817/),min,4,130987,DB01364,Ephedrine
,11824817,limit of quant,The limit of quantitation was 5.8 ng/ml using 0.5 ml of plasma.,Rapid determination of pseudoephedrine in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11824817/),[ng] / [ml],5.8,130988,DB01364,Ephedrine
,17230461,total chromatographic run time,The total chromatographic run time of 2 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Quantification of pseudoephedrine in human plasma by LC-MS/MS using mosapride as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230461/),min,2,139681,DB01364,Ephedrine
,11699608,Elimination half-life,Elimination half-life was approximately 6 h.,Pharmacodynamics and pharmacokinetics of single nasal (5 mg and 10 mg) and oral (50 mg) doses of ephedrine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699608/),h,6,144104,DB01364,Ephedrine
,17294808,flow rate,"The chromatographic separation was achieved within 3.5 min using the mobile phase consisting of methanol/0.05% formic acid (80:20, v/v) and the flow rate was 1.0 ml/min.",Quantification of trimetazidine in human plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294808/),[ml] / [min],1.0,153366,DB01364,Ephedrine
,17294808,m/z,"Ion signals m/z 181.0 and 148.0 were measured in the positive mode for trimetazidine and pseudoephedrine, respectively.",Quantification of trimetazidine in human plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294808/),,181.0,153367,DB01364,Ephedrine
,17294808,m/z,"Ion signals m/z 181.0 and 148.0 were measured in the positive mode for trimetazidine and pseudoephedrine, respectively.",Quantification of trimetazidine in human plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294808/),,148.0,153368,DB01364,Ephedrine
,15752380,clearance,"Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),[l] / [min],0.083,156667,DB01364,Ephedrine
,15752380,clearance,"Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),[l] / [min],0.038,156668,DB01364,Ephedrine
,15752380,volume of distribution,"Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),l,38.6,156669,DB01364,Ephedrine
,15752380,absorption rate constant,"Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),[l] / [min],0.064,156670,DB01364,Ephedrine
,15752380,clearance,"Ephedrine was eliminated mostly renally, with a clearance of 0.34 l min(-1) (CV 11%), and a volume of distribution of 181 l (CV 19%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),[l] / [min],0.34,156671,DB01364,Ephedrine
,15752380,volume of distribution,"Ephedrine was eliminated mostly renally, with a clearance of 0.34 l min(-1) (CV 11%), and a volume of distribution of 181 l (CV 19%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),l,181,156672,DB01364,Ephedrine
,8527687,relative bioavailability,The relative bioavailability of the tablet dosage form with respect to the capsule was found to be 100.8%.,Bioavailability of pseudoephedrine from controlled release formulations in the presence of guaifenesin in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527687/),%,100.8,161285,DB01364,Ephedrine
,16781900,flow rate,The flow rate was 0.8 ml min(-1).,A rapid reversed phase high-performance liquid chromatographic method for determination of sophoridine in rat plasma and its application to pharmacokinetics studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16781900/),[ml] / [min],0.8,166098,DB01364,Ephedrine
,16719539,constant rate,The remainder is released at a constant rate of approximately 5 microg/hour.,Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719539/),[μg] / [h],5,174190,DB01364,Ephedrine
,16719539,steady state,TTS-S attains that concentration after 6 hours; a steady state of about 100 pg/mL is achieved 8-12 hours after application.,Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719539/),[pg] / [ml],100,174191,DB01364,Ephedrine
,8017669,time of onset,The time of onset of surgical anaesthesia was significantly shorter with spinal anaesthesia (7.6 +/- 4.4 vs 31 +/- 11.1 min; p < 0.01).,[Pharmacokinetics of epidural or intrathecal bupivacaine in elective cesarean section]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017669/),min,7.6,174721,DB01364,Ephedrine
,8017669,time of onset,The time of onset of surgical anaesthesia was significantly shorter with spinal anaesthesia (7.6 +/- 4.4 vs 31 +/- 11.1 min; p < 0.01).,[Pharmacokinetics of epidural or intrathecal bupivacaine in elective cesarean section]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017669/),min,31,174722,DB01364,Ephedrine
,8017669,duration,The sensory block had a longer duration in epidural group (223.2 +/- 15 vs 291 +/- 13.8; p < 0.001).,[Pharmacokinetics of epidural or intrathecal bupivacaine in elective cesarean section]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017669/),,291,174723,DB01364,Ephedrine
,27514823,Area under the concentration-time curve from 0 to 360 min (AUC0-t ),"Area under the concentration-time curve from 0 to 360 min (AUC0-t ) of EP, PEP and MEP were 666.99, 650.76 and 632.37 µg·min/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[min·μg] / [ml],666.99,175709,DB01364,Ephedrine
,27514823,Area under the concentration-time curve from 0 to 360 min (AUC0-t ),"Area under the concentration-time curve from 0 to 360 min (AUC0-t ) of EP, PEP and MEP were 666.99, 650.76 and 632.37 µg·min/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[min·μg] / [ml],650.76,175710,DB01364,Ephedrine
,27514823,Area under the concentration-time curve from 0 to 360 min (AUC0-t ),"Area under the concentration-time curve from 0 to 360 min (AUC0-t ) of EP, PEP and MEP were 666.99, 650.76 and 632.37 µg·min/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[min·μg] / [ml],632.37,175711,DB01364,Ephedrine
,27514823,Maximum plasma concentration (C max),"Maximum plasma concentration (C max) of EP, PEP and MEP were 4.15, 4.08 and 3.59 μg/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[μg] / [ml],4.15,175712,DB01364,Ephedrine
,27514823,Maximum plasma concentration (C max),"Maximum plasma concentration (C max) of EP, PEP and MEP were 4.15, 4.08 and 3.59 μg/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[μg] / [ml],4.08,175713,DB01364,Ephedrine
,27514823,Maximum plasma concentration (C max),"Maximum plasma concentration (C max) of EP, PEP and MEP were 4.15, 4.08 and 3.59 μg/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[μg] / [ml],3.59,175714,DB01364,Ephedrine
,27514823,Mean residence time (MRT),"Mean residence time (MRT) of EP, PEP and MEP were 197.00, 173.97 and 183.87 min, respectively, when the rats were treated with EP-PEP-MEP.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),min,197.00,175715,DB01364,Ephedrine
,27514823,Mean residence time (MRT),"Mean residence time (MRT) of EP, PEP and MEP were 197.00, 173.97 and 183.87 min, respectively, when the rats were treated with EP-PEP-MEP.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),min,173.97,175716,DB01364,Ephedrine
,27514823,Mean residence time (MRT),"Mean residence time (MRT) of EP, PEP and MEP were 197.00, 173.97 and 183.87 min, respectively, when the rats were treated with EP-PEP-MEP.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),min,183.87,175717,DB01364,Ephedrine
,12087345,half-lives,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),h,15.5,176054,DB01364,Ephedrine
,12087345,half-lives,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),h,5.6,176055,DB01364,Ephedrine
,12087345,oral clearance,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),[ml] / [min],0.34,176056,DB01364,Ephedrine
,25324527,flow rate,"The separation was performed on a Zorbax SB-Aq column (100 mm × 2.1 mm, 3.5 μm) at a flow rate of 0.3 mL/min using acetonitrile-0.1% formic acid aqueous solution as the mobile phase.",Simultaneous quantification and pharmacokinetics of alkaloids in Herba Ephedrae-Radix Aconiti Lateralis extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25324527/),[ml] / [min],0.3,197506,DB01364,Ephedrine
,22119507,flow rate,"Following liquid-liquid extraction, the analytes were separated on a reversed-phase C(18) column (150 mm × 2.0 mm, 3 μm) using formic acid:10 mM ammonium acetate:methanol (0.2:62:38, v/v/v) as mobile phase at a flow rate of 0.2 mL/min and analyzed by a triple-quadrupole mass spectrometer in the selected reaction monitoring (SRM) mode.","Simultaneous determination of codeine, ephedrine, guaiphenesin and chlorpheniramine in beagle dog plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: application to a bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22119507/),[ml] / [min],0.2,215136,DB01364,Ephedrine
,7438686,p,"We presumed that our patient accumulated the drug because of her persistently alkaline urine, which would favor tubular resorption of this weak base (pKa = 9.4).",Renal excretion of pseudoephedrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438686/),,9.4,217535,DB01364,Ephedrine
,7438686,serum elimination half-life,Increasing urine pH increased the serum elimination half-life from 1.9 to 21 hr.,Renal excretion of pseudoephedrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438686/),h,1.9,217536,DB01364,Ephedrine
,7438686,serum elimination half-life,Increasing urine pH increased the serum elimination half-life from 1.9 to 21 hr.,Renal excretion of pseudoephedrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438686/),h,21,217537,DB01364,Ephedrine
,24824649,m/z,"Detection was based on multiple reaction monitoring with the precursor-to-product ion transitions m/z 166.096-116.983 (ephedrine), m/z 179.034-146.087 (methylephedrine), m/z 456.351-323.074 (amygdalin), and m/z 821.606-351.062 (glycyrrhizic acid).","UPLC-MS/MS determination of ephedrine, methylephedrine, amygdalin and glycyrrhizic acid in Beagle plasma and its application to a pharmacokinetic study after oral administration of Ma Huang Tang. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24824649/),,166,219959,DB01364,Ephedrine
,24824649,m/z,"Detection was based on multiple reaction monitoring with the precursor-to-product ion transitions m/z 166.096-116.983 (ephedrine), m/z 179.034-146.087 (methylephedrine), m/z 456.351-323.074 (amygdalin), and m/z 821.606-351.062 (glycyrrhizic acid).","UPLC-MS/MS determination of ephedrine, methylephedrine, amygdalin and glycyrrhizic acid in Beagle plasma and its application to a pharmacokinetic study after oral administration of Ma Huang Tang. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24824649/),,179.034-146.087,219960,DB01364,Ephedrine
,24824649,m/z,"Detection was based on multiple reaction monitoring with the precursor-to-product ion transitions m/z 166.096-116.983 (ephedrine), m/z 179.034-146.087 (methylephedrine), m/z 456.351-323.074 (amygdalin), and m/z 821.606-351.062 (glycyrrhizic acid).","UPLC-MS/MS determination of ephedrine, methylephedrine, amygdalin and glycyrrhizic acid in Beagle plasma and its application to a pharmacokinetic study after oral administration of Ma Huang Tang. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24824649/),,456.351-323.074,219961,DB01364,Ephedrine
,24824649,m/z,"Detection was based on multiple reaction monitoring with the precursor-to-product ion transitions m/z 166.096-116.983 (ephedrine), m/z 179.034-146.087 (methylephedrine), m/z 456.351-323.074 (amygdalin), and m/z 821.606-351.062 (glycyrrhizic acid).","UPLC-MS/MS determination of ephedrine, methylephedrine, amygdalin and glycyrrhizic acid in Beagle plasma and its application to a pharmacokinetic study after oral administration of Ma Huang Tang. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24824649/),,82,219962,DB01364,Ephedrine
,16672092,Bispectral Index,"For both groups, the objective was to achieve a Bispectral Index of 50.",Feasibility of closed-loop titration of propofol guided by the Bispectral Index for general anaesthesia induction: a prospective randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16672092/),,50,237382,DB01364,Ephedrine
,16672092,duration of,"Bispectral Index overshoot (-9 +/- 13% vs. -16 +/- 20%, P = 0.035) and mean duration of induction (381 +/- 106 s vs. 490 +/- 131 s, P = 0.004) were lower in the closed-loop group than in the TCI group.",Feasibility of closed-loop titration of propofol guided by the Bispectral Index for general anaesthesia induction: a prospective randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16672092/),s,381,237383,DB01364,Ephedrine
,16672092,duration of,"Bispectral Index overshoot (-9 +/- 13% vs. -16 +/- 20%, P = 0.035) and mean duration of induction (381 +/- 106 s vs. 490 +/- 131 s, P = 0.004) were lower in the closed-loop group than in the TCI group.",Feasibility of closed-loop titration of propofol guided by the Bispectral Index for general anaesthesia induction: a prospective randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16672092/),s,490,237384,DB01364,Ephedrine
,16713697,flow-rate,"Chromatographic separation was performed on a Hypurity C18 column (Thermo Hypersil-Keystone 2.1 mm x 150 mm, 5 microm, USA), The mobile phase was composed of 65% methanol and 35% water (contained 0.1% formic acid, 10 mM ammonium formate), which was run with a flow-rate of 0.2 ml/min at 40 degrees C.",Sensitive bioassay for the simultaneous determination of pseudoephedrine and cetirizine in human plasma by liquid-chromatography-ion trap spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713697/),[ml] / [min],0.2,241323,DB01364,Ephedrine
,16713697,limit of detection,The limit of detection for pseudoephedrine and cetirizine each was 5 ng/ml.,Sensitive bioassay for the simultaneous determination of pseudoephedrine and cetirizine in human plasma by liquid-chromatography-ion trap spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713697/),[ng] / [ml],5,241324,DB01364,Ephedrine
higher,28706557,recoveries,The mean recoveries of the three analytes were higher than 75%.,Comparative Pharmacokinetics and Bioavailability of Three Ephedrines in Rat after Oral Administration of Unprocessed and Honey-Fried Ephedra Extract by Response Surface Experimental Design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28706557/),%,75,255765,DB01364,Ephedrine
,493335,plasma clearance,"Average plasma clearance was 67.6 ml/min/kg, with renal clearance averaging 30.3 ml/min/kg.",Pseudoephedrine pharmacokinetics in the rat using a microanalysis technique. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/493335/),[ml] / [kg·min],67.6,258811,DB01364,Ephedrine
,493335,renal clearance,"Average plasma clearance was 67.6 ml/min/kg, with renal clearance averaging 30.3 ml/min/kg.",Pseudoephedrine pharmacokinetics in the rat using a microanalysis technique. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/493335/),[ml] / [kg·min],30.3,258812,DB01364,Ephedrine
,1880721,Bioavailability,Bioavailability of pseudoephedrine was 91% for fed relative to fasted treatment; for brompheniramine it was 89%.,Effect of food on bioavailability of pseudoephedrine and brompheniramine administered from a gastrointestinal therapeutic system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880721/),%,91,259299,DB01364,Ephedrine
,1880721,Bioavailability,Bioavailability of pseudoephedrine was 91% for fed relative to fasted treatment; for brompheniramine it was 89%.,Effect of food on bioavailability of pseudoephedrine and brompheniramine administered from a gastrointestinal therapeutic system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880721/),%,89,259300,DB01364,Ephedrine
